Caxton Corp
- SEC CIK
- 0001388551
- Latest filing
- Aug 13, 2026
Holdings in Q1 2026
Holdings as of Mar 31, 2026, filed May 14, 2026. Long positions only; changes compare share counts with Q4 2025.
- Positions
- 7
- −4 vs. Q4 2025
- Portfolio value
- $4.02M
- −$254.9K (−6.0%) vs. Q4 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| GLDSPDR Gold Trust | ETF | 7,623 | $3.28M | 81.5% | +659+9.5% | Added | History |
| BRK.BBerkshire Hathaway Inc | Stock | 727 | $348.3K | 8.7% | +17+2.4% | Added | History |
| KYTXKyverna Therapeutics, Inc. | COM | 18,773 | $162.0K | 4.0% | 00.0% | Unchanged | History |
| LXEOLexeo Therapeutics, Inc. | COM | 13,943 | $80.0K | 2.0% | 00.0% | Unchanged | History |
| XFORX4 Pharmaceuticals, Inc | COM NEW | 15,557 | $64.2K | 1.6% | 00.0% | Unchanged | History |
| IKTInhibikase Therapeutics, Inc. | COM NEW | 28,453 | $47.8K | 1.2% | 00.0% | Unchanged | History |
| ALXOAlx Oncology Holdings Inc | COM | 20,946 | $42.0K | 1.0% | +20,946 | New | History |
Sold out since Q4 2025 (5)
Positions held at the end of Q4 2025 that are gone from this filing.
| Security | Class | Shares in Q4 2025 | Value in Q4 2025 | % of portfolio in Q4 2025 | History |
|---|---|---|---|---|---|
| SYRESpyre Therapeutics, Inc. | COM NEW | 8,919 | $292.2K | 6.8% | History |
| DFTXDefinium Therapeutics, Inc. | Stock | 15,688 | $210.1K | 4.9% | History |
| CMPXCompass Therapeutics, Inc. | COM | 29,495 | $158.4K | 3.7% | History |
| SABSSAB Biotherapeutics, Inc. | COM NEW | 10,527 | $39.4K | 0.9% | History |
| CNTXContext Therapeutics Inc. | COM | 18,403 | $27.1K | 0.6% | History |